short acting glp 1 GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Comparison of short-acting versus long-acting

avoid Pediatric use not indicated outside controlled GH-deficiency treatment Regulatory Status (as of April 2026) Both ipamorelin and CJC-1295 were removed from the FDA Section 503A bulks list in September 2024, restricting compounding-pharmacy access

Insights into the structure of class B GPCRs

The absence of pituitary stimulation changes its signaling profile compared to GH secretagogues

A study published in 2025, in which researchers interviewed 29 users of the drug, found that "participants were generally unconcerned with long-term adverse effects and instead perceived that [melanotan II] was protective against skin cancer by preventing sunburn"